CEO succession is routine and non-material for stock performance. Monitor any strategic shifts or pipeline updates under Severino's leadership, particularly in Duchenne programs and siRNA pipeline. The orderly transition (Ingram advising through year-end) reduces execution risk.
SRPT drugs
SRPT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 27 $15.89entry
- T+1 · 4mo ago −2.89%α −3.13% · $15.43
- T+5 · 4mo ago −6.48%α −7.56% · $14.86
- T+20 · 3mo ago +14.10%α +10.80% · $18.13
- T+60 · 28d ago +11.58%α +7.87% · $17.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is retiring and will serve as a consultant through December 31, 2026. Severino brings extensive R&D and leadership experience from AbbVie and Tessera Therapeutics, and will receive a compensation package including a $1.18M base salary, 110% target bonus, and a $35M sign-on equity grant.
Key Facts
- Michael Severino appointed CEO and Class I director effective July 28, 2026
- Douglas Ingram retires as CEO and board member, enters consulting agreement at $15,000/month through Dec 31, 2026
- Severino's base salary: $1,180,000 per year; target bonus: 110% of base salary
- Sign-on equity grant: ~$35,000,000 in RSUs and premium-priced stock options vesting over 4 years
- Severino previously served as CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie
Financial Impact
CEO compensation: $1,180,000 base salary, ~$35,000,000 sign-on equity grant; outgoing CEO consulting fee: $15,000/month
Risk Factors
- Execution risk during leadership transition
- Potential strategic pivot away from current Duchenne-focused strategy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (SRPT), Batch item 1 | 0001193125-26-316995 |
| Document: d101719d8k.htm | 0001193125-26-316995 |
| Document: d101719dex102.htm | 0001193125-26-316995 |
| Document: d101719dex991.htm | 0001193125-26-316995 |
| Document: 0001193125-26-316995-index-headers.html | 0001193125-26-316995 |
| Document: 0001193125-26-316995-index.html | 0001193125-26-316995 |
| Document: 0001193125-26-316995.txt | 0001193125-26-316995 |
| 8-K Filing (SRPT), Batch item 8 | 0001193125-26-316995 |
Track record
9 reports on SRPT
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $16.07 Now $15.13 −5.85% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.42 Now $15.13 −7.86% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $17.82 Now $15.13 −15.10% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $18.54 Now $15.13 −18.39% settles Dec 2
- Jul 27, 202616w ago 8-K Neutral 3/10 Viewing Entry $15.89 to $18.13 Now $15.13 −4.78% ▲ +14.10% +10.80% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $15.00 to $20.52 Now $15.13 +0.87% ▲ +36.80% +34.91% vs SPY
- Jun 4, 202623w ago 8-K Neutral 3/10 Entry $15.75 to $19.18 Now $15.13 −3.94% ▲ +21.78% +19.92% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $20.89 to $16.67 Now $15.13 −27.56% ▼ −20.18% −25.14% vs SPY
- Feb 25, 202637w ago 8-K Mixed 7/10 Entry $17.45 to $21.68 Now $15.13 −13.30% ▲ +24.24% +30.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers